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ANTI-AGING PHARMACOLOGY: PROMISES AND PITFALLS 
Introduction. Life expectancy has grown dramatically in modern times. This 
increase, however, is not accompanied by the same increase in healthspan. Efforts to 
extend healthspan through pharmacological agents targeting aging-related 
pathological changes are now in the spotlight of geroscience, the main idea of which 
is that delaying of aging is far more effective than preventing the particular chronic 
disorders. Currently, anti-aging pharmacology is a rapidly developing discipline. It is 
a preventive field of health care, as opposed to conventional medicine which focuses 
on treating symptoms rather than root causes of illness. [1, p.3]. 
Aim. This review is focused on current advances and perspectives in the field of 
anti-aging pharmacology. 
Few decades ago, it was generally believed that damage induced by free radicals 
is a primary cause of aging and, thereby, that antioxidants may protect against this 
damage, consequently slowing the aging process and improving health. Currently, it 
is becoming apparent that a single cause could not properly explain the health- and 
lifespan-promoting effects of different pharmacological classes. It is increasingly 
clear that pro-longevity effects of many prospective antiaging agents are complex and 
could be attributable to numerous interacting signaling pathways. Taking into account 
the exceptional complexity of mechanistic pathways underlying aging, the 
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identification of these pathways and development of relevant anti-aging interventions 
seems to be a challenging task. Considerable progress, however, has been made in 
this research field throughout the past years. A large number of pharmacological 
substances having the potential to target molecular pathways underlying aging and to 
induce protective responses against aging-associated diseases including, e.g., mTOR 
inhibitors such as rapamycin, senolytics, etc, are presently under investigation.  
One important issue in the study of potential geroprotective agents is that their 
pro-longevity effects might be mediated by the prevention and/or delay of onset of 
age-associated, life-shortening diseases, rather than through inhibiting the aging 
processes itself. For example, Neff et al. (2013) and Ehninger et al. (2014) based on a 
large-scale assessment of more than 150 cellular, molecular, histopathological, and 
functional traits, which typically change during the course of aging, in rapamycin-
treated mice, concluded that rapamycin can extend longevity, but it has only limited 
effect on the aging process per se. Another promising anti-aging drug candidate, 
resveratrol, was found to be able to extend life span in mice fed with high-fat diet by 
reversing the initial steps of particular age-related diseases induced by that diet, but 
had no effect on animals fed with healthy diet.  
Thus, all known pro-longevity drugs can be divided in three categories in 
accordance with the suggested mode of action:  
- those demonstrating anti-aging effects, but without any evidence yet of their 
ability to prolong life;  
- those that are suggested to extend longevity primarily because they can prevent 
or postpone the progression of particular age-related disease, such as cancer, but 
which are not proven to delay the aging process(es) per se;  
- those that extend longevity because they are actually suggested to reverse the 
aging process itself, at least in certain environments [2, p.221]. 
Based on these considerations, the most promising agents with suspected anti-
aging properties are categorized into three main groups in the Table 1. Since the 
fundamental purpose of anti-aging medicine is ultimately an extension of the healthy 
human life, only evidence for life extension obtained in mammalian models are 
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shown in the table. Certainly, the classification presented in this table is quite 
conditional since only relatively few research findings have been reported until now 
in this area of investigation, thus any new data can move a particular substance from 
one category to another.  
In summarizing it may be suggested that targeting aging per se may be more 
efficient approach to prevent or postpone age-related diseases than treatments 
targeted to particular pathological conditions. Because of the aging population, this 
therapeutic strategy undoubtedly can be an area of increasing relevance for the 
pharmaceutical industry and public health organizations. It is currently assumed that 
great socio-economic benefits can be obtained from the approach based on the 
longevity dividend paradigm in comparison with modern public health strategy aimed 
on the prevention of particular diseases. Presently, the consensus is among medical 
and health professionals that the optimization of physiological and mental 
functioning through the life course should be a main focus of public health policy 
addressing the problem of global aging. A healthy lifestyle including a balanced diet, 
regular exercise and smoking cessation is the first-line strategy. Using the 
pharmacological substances, both potential and existing, may serve as a prospective 
additional approach [1, p.41-43] 
Table 1. Summary and categorization of the most promising anti-aging 
agents 
Preparation Effects observed 
AO DR AI AC AP NP AA GHS TA LE 
Agents with no observed demographic effects until now 
2-deoxy-D-
glucose 
 +  + +      
Pegvisomant +   +    +   
Agents suggesting to promote longevity mainly by inhibiting particular disease(s) 
Statins   + + + + +   + 
Rapamycin + + + +   + +  + 
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Agents with both anti-aging and pro-longevity effects 
Aspirin  + +    +   + 
Coenzyme 
Q10 
+ + +   + +   + 
Spermidine + + +  +   +  + 
Vitamin E    +      + 
Sodium 
butyrate 




+  + + + +    + 
Melatonin +  + + + +  +  + 
 
AO: antioxidant; DR: dietary restriction; AI: anti-inflammatory; AC: anti-
cancerous; AP: autophagy; NP: neuroprotective; AA: anti-atherogenic; GHS: growth 
hormone suppression; TA: telomerase activation; LE: life extension [1, p.89].  
Conclusions. The great expectations related to further development of anti-
aging interventions, however, must certainly be critically discussed and explored in 
the light of their economic, social and ethical implications. The implementation of 
these approaches in clinical practice will be possible only after in-depth examination 
and further comprehensive discussion. To meet the needs caused by the rapid 
population aging across the globe, a novel emphasis in physiological geroscience is 
needed which will require the joint efforts of interdisciplinary investigators working 
throughout the continuum of translational medicine from basic research to clinical 
applications [1, p.43] 
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ECONOMIC FREEDOM AS AN IMPORTANT PRECONDITION OF 
BUSINESS FUNCTIONING 
The purpose of this study is the consideration of the concept and components of 
economic freedom and its importance. Accordingly, the subject of the study is 
economic freedom as the ability of members of a society to undertake economic 
actions [1]. The components of economic liberty are private property, freedom of 
entrepreneurship, freedom of custom choice, the optimal level of state regulation [2]. 
During the writing the study the theoretical and empirical research methods 
were used. 
The role of economic freedom is extremely high. It provides «a formula for 
economic progress and success». The actuality of my report lies in the fact that there 
are many incipient economic changes in the Ukraine that impact on the material well-
being of each member of our society. That is why we need to know in which 
direction to implement these economic changes and decisions, what should guide us 
in the development of the national economy and what should be categorically 
abolished. Thus, large economic losses can be avoided and economic benefits can be 
maximized. 
The result of the study was as follows. The most important component of 
economic freedom is availability of private property. The private property is a right to 
dispose, use and control certain resources by individuals or their groups. A private 
